Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis

Hepatology

Volumn 55, Issue 2, 2012, Pages 655-656

  Kalambokis, Georgios N ^a   Tsianos, Epameinondas V ^a  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; ENDOTOXIN; NEOMYCIN; PAROMOMYCIN; PROBIOTIC AGENT; PROTHROMBIN; RIFAXIMIN; SERUM ALBUMIN; SYNBIOTIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIMICROBIAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; DRUG USE; ENDOTOXEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTESTINE FLORA; LETTER; LIVER FUNCTION; LIVER GRAFT; LIVER INJURY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING;

ANIMALS; DRUG-INDUCED LIVER INJURY; ENDOTOXINS; HUMANS;

EID: 84856407574     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24751     Document Type: Letter

References (8)

1. Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. HEPATOLOGY 2010; 52: 1829-1835.
2. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic, and peripheral blood in patients with cirrhosis. HEPATOLOGY 1988; 8: 232-236.
3. Pérez del Pulgar S, Pizcueta P, Engel P, Bosch J. Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension. J Hepatol 2000; 32: 25-31.
4. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. HEPATOLOGY 2004; 39: 1441-1449.
5. Lata J, Novotny I, Pribramska V, Jurankova J, Fric P, Kroupa R, et al. The effect of probiotics on gut flora, level of endotoxin, and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol 2007; 19: 1111-1113.
6. Tarao K, Iwamura K. Effect of long-term administration of paromomycin sulfate on the level of serum albumin and gamma-globulin in human cirrhosis. Tokai J Exp Clin Med 1983; 8: 349-357.
7. Madrid AM, Hurtado C, Venegas M, Cumsille F, Defilippi C. Long-term treatment with cisapride and antibiotics in liver cirrhosis: effect on small intestinal motility, bacterial overgrowth, and liver function. Am J Gastroenterol 2001; 96: 1251-1255.
8. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26: 17-25.